RecruitingAlzheimer DiseaseMild Cognitive ImpairmentDementia
Study to Understand Novel Biomarkers in Researching Dementia
Eligible age
60+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis. We aim to understand how well blood-based biomarkers can diagnose and predict Alzheimer's disease, which will help to further develop and validate blood tests for the disease.
Sponsor: Washington University School of Medicine
You may qualify if…
- ✓ At least 60 years of age
- ✓ 80% of the newly enrolled clinic-based cohort will have symptoms of forgetfulness, mild cognitive impairment, mild dementia, or Alzheimer's disease as determined by their medical chart and/or provider
- ✓ All SEABIRD participants will be invited to participate regardless of their cognitive status
You may not qualify if…
- ✕ Unable to perform one or more basic activities of daily living (eating, bathing, dressing, ambulating, toileting) due to cognitive impairment
- ✕ Uncontrolled hepatitis B, hepatitis C, or HIV at time of blood collection
- ✕ Taking a disease-modifying drug for AD at time of enrollment
- ✕ Blood transfusion in the last three months
- ✕ Unwilling or unable to participate in all study activities
Where it's recruiting
Missouri
St Louis
Source: ClinicalTrials.gov · NCT06547099 · last updated 2026-01-16